Comparison of Docosahexaenoic (DHA) Values in Patients With Polycystic Ovary Syndrome (PCOS)
1 other identifier
observational
138
1 country
1
Brief Summary
Although PCOS has been known for many years, its etiology and treatment are not clearly known. The prevalence of PCOS varies between populations. It is a familial endocrinolpathology with a chronic course, multifactorial, polygenic feature seen with an average prevalence of 6-8% in women in the reproductive period.Chronic inflammation is involved in the pathophysiology of many chronic diseases. PCOS, which is a proinflammatory condition, has been associated with insulin resistance and hyperandrogenism in previous studies. Omega-3 fatty acids have anti-inflammatory, anti-thrombotic, anti-arrhythmic properties, reducing lipid levels such as serum triglyceride and LDL cholesterol, and having positive effects on the immune system. Therefore, their deficiencies include fatigue, joint pain, frequent infections, etc. is seen. Omega-6 fatty acids have the opposite effect. DHA is a member of the omega-3 fatty acids family. Dietary components play an important role in chronic inflammation. According to our literature review, there is no study that detects docosahexaenoic acid (DHA) levels in blood and cervical mucus samples in patients with PCOS. We think that we will contribute to the diagnosis and treatment processes of PCOS patients by detecting DHA levels in this study. In this study, we aim to compare the values of docosahexaenoic acid (DHA) in serum and cervical mucus samples in patients with polycystic ovary syndrome with the control group.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 24, 2022
CompletedFirst Posted
Study publicly available on registry
October 27, 2022
CompletedStudy Start
First participant enrolled
November 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2023
CompletedOctober 27, 2022
October 1, 2022
3 months
October 24, 2022
October 24, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Blood DHA levels of patients with PCOS
Blood DHA levels of patients with PCOS
3 months
Cervical mucus DHA levels of patients with PCOS
Cervical mucus DHA levels of patients with PCOS
3 months
Study Arms (2)
Blood DHA levels of patients with PCOS
The patients diagnosed as PCOS according to Rotterdam criteria will be the study group. The DHA leves in blood sample of the patients will be recorded
BloodDHA levels of the control group
The patients without PCOS will be control group. The DHA leves in blood sample of the patients will be recorded
Interventions
DHA levels of blood and cervical mucus of the control and the study groups will be measure
Eligibility Criteria
the patients diagnosed as PCOS according to Rotterdam criteria will be accepted as study group
You may qualify if:
- Patients with polycystic ovary syndrome
You may not qualify if:
- Pregnancy
- Malignity
- postmenopause
- diagnosis of congenital adrenal syndrome
- Oral contraseptive use at last 3 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Recep Tayyip Erdogan Univercity
Rize, 33090, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant professor
Study Record Dates
First Submitted
October 24, 2022
First Posted
October 27, 2022
Study Start
November 1, 2022
Primary Completion
February 1, 2023
Study Completion
February 1, 2023
Last Updated
October 27, 2022
Record last verified: 2022-10